Peptide · Fact sheet

Trofinetide

Also known as Daybue · NNZ-2566

Trofinetide is FDA approved as Daybue for Rett syndrome in adults and children 2 years and older. It is not approved as a general cognitive, developmental, neuroprotective, or anti-aging peptide.

FDA approved for specific usesStrong human evidence for approved uses

What is Trofinetide?

Trofinetide is a synthetic analog of glycine-proline-glutamate, a three-amino-acid fragment related to insulin-like growth factor 1 biology.

The approved claim rests on changes in caregiver- and clinician-rated Rett syndrome measures, not a cure or reversal of the condition.

Benefits & claims

Rett syndrome is a rare neurodevelopmental disorder with major communication, movement, and daily-function effects.

Its approval shows that a very small peptide analog can become a condition-specific neurology medicine, but does not validate broader brain-enhancement claims.

What the evidence supports

  • The pivotal trial found better average change than placebo on a caregiver-rated Rett symptom score and a clinician global-impression measure.
  • The trial did not establish a cure, disease reversal, or benefit outside Rett syndrome.
Research areas
  • Rett syndrome symptoms
  • Communication and behavior
  • Neurodevelopmental function
  • Longer-term Rett syndrome outcomes and functional effects

Dosage & frequency

Product-specific label information

Daybue and Daybue STIX use twice-daily, weight-based amounts for Rett syndrome. A single fixed adult dose would be misleading.

Daybue / Daybue STIX

Adults and pediatric patients age two years and older with Rett syndrome

Amount
9–<12 kg: 5,000 mg; 12–<20 kg: 6,000 mg; 20–<35 kg: 8,000 mg; 35–<50 kg: 10,000 mg; ≥50 kg: 12,000 mg per dose
Frequency
Twice daily
Route studied or labeled
Oral

Weight bands; moderate renal impairment requires lower amounts.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • Oral solution and oral-solution powder packets have the same active ingredient but different presentation.

Interactions & precautions

  • The label cautions that exposure to sensitive CYP3A and/or P-gp substrates can increase; loperamide was studied as an example.

What is still unresolved

  • Renal function and adverse effects can require a different regimen.

Side effects & risks

  • Diarrhea and vomiting are prominent labeled adverse reactions and can be severe.
  • The label warns about weight loss and the need for clinical monitoring.
  • Long-term real-world effectiveness and tolerability may differ from the pivotal trial.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Strong human evidence for approved uses

A randomized Phase 3 trial supported statistically significant but modest changes on Rett-specific symptom scales. Evidence is condition-specific and does not establish restoration of lost function or benefit in other neurologic disorders.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 3 sourced accounts by reported effect.

Pain: reported experiences

Mixed account · personal report

Less stomach distress, with persistent diarrhea

In a caregiver roundtable, Lindsay Reardon described less screaming and discomfort in her daughter, but diarrhea continuing beyond a year.

Reported use in this account

Product
Trofinetide study medicine
Amount
Not specified clearly
Frequency
Not specified clearly
Route
Feeding tube
Duration
More than one year

Acadia funded this selected caregiver roundtable. Pre-existing digestive problems complicate interpretation.

Read the original accounts

Approval status

FDA-approved Daybue labeling covers treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.

Approved uses

  • Treatment of Rett syndrome in adults and pediatric patients 2 years of age and older under the Daybue label

FDA approved for Rett syndrome

Trofinetide is approved under the Daybue label for Rett syndrome in specified ages. The approval should not be generalized to other neurodevelopmental or cognitive claims.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Durability of functional benefit over many years
  • Which individual characteristics predict meaningful response
  • Effects on outcomes not captured well by the pivotal rating scales
  • Whether related peptide analogs could help other neurodevelopmental disorders

Summary

Daybue is approved for Rett syndrome. Average trial benefits were modest, and gastrointestinal effects often limited tolerability.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. fdaFDA prescribing information: Daybue

    Current approved indication, warnings, adverse reactions, and pivotal-study summary.

  2. pubmedLAVENDER randomized Phase 3 trial

    Pivotal controlled study of Rett-specific symptom and global-impression outcomes.

  3. fdaFDA multidisciplinary review: Daybue

    FDA review of efficacy, safety, trial interpretation, and approval considerations.

  4. nihDaybue and Daybue STIX current prescribing information

    Primary source for the practical reference information.

How we assess sources · Suggest a correction